Blood Biomarker of Alzheimer's Disease (AD)
| Status: | Recruiting |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 1/13/2019 |
| Start Date: | March 12, 2018 |
| End Date: | May 2019 |
| Contact: | Kristina Balderson |
| Email: | kristina.balderson@duke.edu |
| Phone: | 919-684-0071 |
mtDNA Damage in Alzheimer's Disease (AD)
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This
is partially due to the inability to detect the disease before it has progressed to a stage
where there are clinical manifestations. The identification and validation of high throughput
biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is
critical to the development of disease-modifying or even preventative therapies. In this
study, we are testing a blood biomarker for stratification of Alzheimer's disease patients
and healthy volunteers. This study may lead to future blood tests that may help earlier
diagnosis of Alzheimer's disease and detect the disease progression.
is partially due to the inability to detect the disease before it has progressed to a stage
where there are clinical manifestations. The identification and validation of high throughput
biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is
critical to the development of disease-modifying or even preventative therapies. In this
study, we are testing a blood biomarker for stratification of Alzheimer's disease patients
and healthy volunteers. This study may lead to future blood tests that may help earlier
diagnosis of Alzheimer's disease and detect the disease progression.
Inclusion Criteria:
Alzheimer's Disease Patients:
- 50 years and older
- AD patient who is seen at the Memory Disorders Clinic
- AD diagnosis
- Non smoking
- No cancer treatment in the last 5 years
- Informed consent from the patient or the patient's legally authorized representative
(LAR)
- Patient and/or LAR able to read and speak English
Healthy Control Participants:
- 50 years and older
- Non smoking
- No cancer treatment in the last 5 years
- Age matched to AD subject
- Able to read and speak English
Exclusion Criteria:
Alzheimer's Disease Patients:
- Known additional neurological disease
Healthy Control Participants:
- Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
We found this trial at
1
site
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: Laurie Sanders, PhD
Phone: 919-684-0071
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
